Search

Your search keyword '"Melaiu O"' showing total 75 results

Search Constraints

Start Over You searched for: Author "Melaiu O" Remove constraint Author: "Melaiu O"
75 results on '"Melaiu O"'

Search Results

51. Impact of Natural Occurring ERAP1 Single Nucleotide Polymorphisms within miRNA-Binding Sites on HCMV Infection.

52. EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma.

53. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.

54. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases.

55. Functional polymorphism within NUP210 encoding for nucleoporin GP210 is associated with the risk of endometriosis.

56. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP.

57. Counter-regulation of regulatory T cells by autoreactive CD8 + T cells in rheumatoid arthritis.

58. Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.

59. The genetic susceptibility in the development of malignant pleural mesothelioma.

60. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.

61. Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immunoevasion.

63. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

64. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

65. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

66. Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

67. Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma.

68. Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma.

69. A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma.

70. Expression status of candidate genes in mesothelioma tissues and cell lines.

71. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

72. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

73. Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24.

74. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.

75. A methodological reappraisal of total and high molecular weight adiponectin determination in human peripheral circulation: comparison of four immunometric assays.

Catalog

Books, media, physical & digital resources